Sentence examples for clinical policymaking from inspiring English sources

So, there are many situations where the use of evidence in clinical policymaking is still very difficult.

Furthermore, the development within some health care systems of various policymaking structures that act as receptor bodies for research, such as the National Institute for Health and Clinical Excellence NICEE) in the UK, has considerably extended the opportunities for research to be used in policymaking, and especially in clinical policymaking [ 6].

We therefore focused on the possibility of there being more than just small and perhaps clinically insignificant effects, i.e. the possibility of effects that one would reasonably consider to be of clinical and policymaking interest.

However, clinical decision-making is a fundamentally different process from policymaking.

This specific area of inquiry is uniquely situated between two more extensively-researched bodies of literature in the field of evidence-based decision-making: 1) the development and implementation of clinical practice guidelines (CPGs), and 2) evidence-based health policymaking.

The interaction of such symptoms with chronic diseases should be acknowledged and considered in the clinical setting as well as in health care planning and policymaking.

Policymakers and other stakeholders in HEPA policymaking should therefore clearly face, solve, and manage the use of research evidence in policymaking and realise true evidence-informed policymaking.

This study aims to evaluate the impact that policymaking and national recommendations for normal childbirth care have on clinical practice.

Chapters examine such topics as national cloning and xenotransplant policies; the politics of stem cell research in Britain, Germany, and Italy; DNA profiling and DNA databases in criminal law; clinical trials in India and the United States; the GM crop controversy in Britain; and precautionary policymaking in the European Union.

Over the past decade, questionnaires have therefore become widely used as outcome measures in clinical trials 2 and rating scale data are becoming integral to patient care, prescribing and policymaking.

Ultimately, the lack of clinical and scientific knowledge on the risks and potential harm reduction benefits has led to precautionary policymaking, which often lacks grounding in empirical evidence and results in spatially uneven diffusion of policy.